[96a5a0]: / output / allTrials / identified / NCT05895994_identified.json

Download this file

685 lines (685 with data), 29.1 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
{
"info": {
"nct_id": "NCT05895994",
"official_title": "A Study on the Efficacy, Safety and Cellular Pharmacokinetics of RD13-02 Cell Injection in Patients With Relapsed or Refractory CD7-positive Hematological Malignancies",
"inclusion_criteria": "1. Age 3-70\n2. Diagnosis of r/r T-ALL/LBL/AML.\n3. CD7 positive expression\n4. Bone marrow lymphoblasts ≥5% by morphologic evaluation at screening\n5. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min, Serum alanine aminotransferase(ALT)/aspartate aminotransferase(AST) < 3×upper limit of normal, Total bilirubin < 1.5×upper limit of normal or ≤1.5mg/dl\n6. Left ventricular ejection fraction ≥ 50% .\n7. Baseline oxygen saturation ≥ 92% on room air.\n8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n9. The estimated survival time is more than 3 months.\n10. Subjects or their legal guardians volunteer to participate in the study and sign the informed consent.\nHealthy volunteers allowed\nMust have minimum age of 3 Years\nMust have maximum age of 70 Years",
"exclusion_criteria": "1. Subjects with concomitant genetic syndromes associated with bone marrow failure states.\n2. Isolated extramedullary lesions\n3. Subjects with some cardiac conditions will be excluded.\n4. With uncontrolled active central nervous system leukemia (CNSL), cerebrospinal fluid grade Central Nervous System3(CNS3).\n5. History of traumatic brain injury, consciousness disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic disease, which might compromise the ability of the subject to compliance with the obligations under the protocol.\n6. History of malignancy other than non-melanoma skin cancer or carcinoma.\n7. Primary immune deficiency.\n8. Presence of uncontrolled infections.\n9. Subjects with some anticancer therapy before CAR-T infusion will be excluded.\n10. Active uncontrolled acute infections.\n11. Known history of infection with human immunodeficiency virus (HIV); active or latent hepatitis B, hepatitis C and syphilis.\n12. Subjects who are receiving systemic steroid therapy prior to screening.\n\n14.Having received live/attenuated vaccine within 4 weeks prior to screening. 15.History of allergy to any component of the cell therapy product. 16.Pregnant or breastfeeding women 17.Any other issue which, in the opinion of the investigator, would make the subjects ineligible for the study.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. Age 3-70",
"criterions": [
{
"exact_snippets": "Age 3-70",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 3,
"unit": "years"
},
{
"operator": "<=",
"value": 70,
"unit": "years"
}
]
}
}
]
}
]
},
{
"line": "2. Diagnosis of r/r T-ALL/LBL/AML.",
"criterions": [
{
"exact_snippets": "Diagnosis of r/r T-ALL",
"criterion": "T-ALL",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": "r/r"
}
]
},
{
"exact_snippets": "Diagnosis of ... LBL",
"criterion": "LBL",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": "r/r"
}
]
},
{
"exact_snippets": "Diagnosis of ... AML",
"criterion": "AML",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": "r/r"
}
]
}
]
},
{
"line": "3. CD7 positive expression",
"criterions": [
{
"exact_snippets": "CD7 positive expression",
"criterion": "CD7 expression",
"requirements": [
{
"requirement_type": "expression",
"expected_value": "positive"
}
]
}
]
},
{
"line": "4. Bone marrow lymphoblasts ≥5% by morphologic evaluation at screening",
"criterions": [
{
"exact_snippets": "Bone marrow lymphoblasts ≥5% by morphologic evaluation at screening",
"criterion": "bone marrow lymphoblasts",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 5,
"unit": "%"
}
},
{
"requirement_type": "evaluation method",
"expected_value": "morphologic evaluation"
},
{
"requirement_type": "timing",
"expected_value": "at screening"
}
]
}
]
},
{
"line": "5. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min, Serum alanine aminotransferase(ALT)/aspartate aminotransferase(AST) < 3×upper limit of normal, Total bilirubin < 1.5×upper limit of normal or ≤1.5mg/dl",
"criterions": [
{
"exact_snippets": "Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min",
"criterion": "creatinine clearance",
"requirements": [
{
"requirement_type": "estimation method",
"expected_value": "Cockcroft Gault"
},
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "mL/min"
}
}
]
},
{
"exact_snippets": "Serum alanine aminotransferase(ALT)/aspartate aminotransferase(AST) < 3×upper limit of normal",
"criterion": "serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST)",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": "<",
"value": 3,
"unit": "×upper limit of normal"
}
}
]
},
{
"exact_snippets": "Total bilirubin < 1.5×upper limit of normal or ≤1.5mg/dl",
"criterion": "total bilirubin",
"requirements": [
{
"requirement_type": "value",
"expected_value": [
">",
"1.5×upper limit of normal",
"≤1.5mg/dl"
]
}
]
}
]
},
{
"line": "6. Left ventricular ejection fraction ≥ 50% .",
"criterions": [
{
"exact_snippets": "Left ventricular ejection fraction ≥ 50%",
"criterion": "left ventricular ejection fraction",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "%"
}
}
]
}
]
},
{
"line": "7. Baseline oxygen saturation ≥ 92% on room air.",
"criterions": [
{
"exact_snippets": "Baseline oxygen saturation ≥ 92%",
"criterion": "oxygen saturation",
"requirements": [
{
"requirement_type": "baseline level",
"expected_value": {
"operator": ">=",
"value": 92,
"unit": "%"
}
}
]
},
{
"exact_snippets": "on room air",
"criterion": "oxygen saturation",
"requirements": [
{
"requirement_type": "condition",
"expected_value": "room air"
}
]
}
]
},
{
"line": "8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "9. The estimated survival time is more than 3 months.",
"criterions": [
{
"exact_snippets": "The estimated survival time is more than 3 months.",
"criterion": "estimated survival time",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "months"
}
}
]
}
]
},
{
"line": "10. Subjects or their legal guardians volunteer to participate in the study and sign the informed consent.",
"criterions": [
{
"exact_snippets": "Subjects or their legal guardians volunteer to participate in the study",
"criterion": "voluntary participation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "sign the informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 3 Years",
"criterions": [
{
"exact_snippets": "minimum age of 3 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 70 Years",
"criterions": [
{
"exact_snippets": "maximum age of 70 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 70,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Subjects with concomitant genetic syndromes associated with bone marrow failure states.",
"criterions": [
{
"exact_snippets": "concomitant genetic syndromes associated with bone marrow failure states",
"criterion": "genetic syndromes",
"requirements": [
{
"requirement_type": "association",
"expected_value": "bone marrow failure states"
}
]
}
]
},
{
"line": "2. Isolated extramedullary lesions",
"criterions": [
{
"exact_snippets": "Isolated extramedullary lesions",
"criterion": "extramedullary lesions",
"requirements": [
{
"requirement_type": "isolation",
"expected_value": true
}
]
}
]
},
{
"line": "3. Subjects with some cardiac conditions will be excluded.",
"criterions": [
{
"exact_snippets": "cardiac conditions",
"criterion": "cardiac conditions",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "4. With uncontrolled active central nervous system leukemia (CNSL), cerebrospinal fluid grade Central Nervous System3(CNS3).",
"criterions": [
{
"exact_snippets": "uncontrolled active central nervous system leukemia (CNSL)",
"criterion": "central nervous system leukemia (CNSL)",
"requirements": [
{
"requirement_type": "control status",
"expected_value": "uncontrolled"
},
{
"requirement_type": "activity status",
"expected_value": "active"
}
]
},
{
"exact_snippets": "cerebrospinal fluid grade Central Nervous System3(CNS3)",
"criterion": "cerebrospinal fluid grade",
"requirements": [
{
"requirement_type": "grade",
"expected_value": "Central Nervous System3 (CNS3)"
}
]
}
]
},
{
"line": "5. History of traumatic brain injury, consciousness disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic disease, which might compromise the ability of the subject to compliance with the obligations under the protocol.",
"criterions": [
{
"exact_snippets": "History of traumatic brain injury",
"criterion": "traumatic brain injury",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "History of ... consciousness disturbance",
"criterion": "consciousness disturbance",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "History of ... epilepsy",
"criterion": "epilepsy",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "History of ... cerebrovascular ischemia",
"criterion": "cerebrovascular ischemia",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "History of ... cerebrovascular hemorrhagic disease",
"criterion": "cerebrovascular hemorrhagic disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "6. History of malignancy other than non-melanoma skin cancer or carcinoma.",
"criterions": [
{
"exact_snippets": "History of malignancy other than non-melanoma skin cancer or carcinoma.",
"criterion": "history of malignancy",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": [
"non-melanoma skin cancer",
"carcinoma"
]
}
]
}
]
},
{
"line": "7. Primary immune deficiency.",
"criterions": [
{
"exact_snippets": "Primary immune deficiency",
"criterion": "primary immune deficiency",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "8. Presence of uncontrolled infections.",
"criterions": [
{
"exact_snippets": "Presence of uncontrolled infections",
"criterion": "uncontrolled infections",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "9. Subjects with some anticancer therapy before CAR-T infusion will be excluded.",
"criterions": [
{
"exact_snippets": "anticancer therapy before CAR-T infusion",
"criterion": "prior anticancer therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "10. Active uncontrolled acute infections.",
"criterions": [
{
"exact_snippets": "Active uncontrolled acute infections",
"criterion": "acute infections",
"requirements": [
{
"requirement_type": "control status",
"expected_value": "uncontrolled"
},
{
"requirement_type": "activity status",
"expected_value": "active"
}
]
}
]
},
{
"line": "11. Known history of infection with human immunodeficiency virus (HIV); active or latent hepatitis B, hepatitis C and syphilis.",
"criterions": [
{
"exact_snippets": "Known history of infection with human immunodeficiency virus (HIV)",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "active or latent hepatitis B",
"criterion": "hepatitis B",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"active",
"latent"
]
}
]
},
{
"exact_snippets": "active or latent ... hepatitis C",
"criterion": "hepatitis C",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"active",
"latent"
]
}
]
},
{
"exact_snippets": "active or latent ... syphilis",
"criterion": "syphilis",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"active",
"latent"
]
}
]
}
]
},
{
"line": "12. Subjects who are receiving systemic steroid therapy prior to screening.",
"criterions": [
{
"exact_snippets": "Subjects who are receiving systemic steroid therapy",
"criterion": "systemic steroid therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "14.Having received live/attenuated vaccine within 4 weeks prior to screening. 15.History of allergy to any component of the cell therapy product. 16.Pregnant or breastfeeding women 17.Any other issue which, in the opinion of the investigator, would make the subjects ineligible for the study.",
"criterions": [
{
"exact_snippets": "Having received live/attenuated vaccine within 4 weeks prior to screening.",
"criterion": "live/attenuated vaccine",
"requirements": [
{
"requirement_type": "time since administration",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "History of allergy to any component of the cell therapy product.",
"criterion": "allergy to cell therapy product",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Pregnant or breastfeeding women",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "status",
"expected_value": true
}
]
},
{
"exact_snippets": "Pregnant or breastfeeding women",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "status",
"expected_value": true
}
]
},
{
"exact_snippets": "Any other issue which, in the opinion of the investigator, would make the subjects ineligible for the study.",
"criterion": "investigator's opinion on eligibility",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": "ineligible"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}